Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
CORT sits 25% above its 52-week low of $28.66.
Summary
A securities class action lawsuit has been filed against Corcept Therapeutics and its executives, alleging failure to disclose material information regarding the FDA approval prospects of relacorilant. This lawsuit stems from the FDA's Complete Response Letter (CRL) for relacorilant, which was disclosed on December 31, 2025, and led to a 50.4% stock decline. The company's recent 10-K, filed on February 24, 2026, also highlighted this CRL as a driver of declining profitability. This development introduces new legal and financial risks for Corcept, adding to recent negative news regarding patent disputes and the FDA CRL.
At the time of this announcement, CORT was trading at $35.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $28.66 to $117.33. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Acceswire.